Unnatural Products, a Santa Cruz, CA-based biotech company pairing AI with chemistry for molecularly targeted therapeutics, raised $32M in Series A funding.
The round was led by Merck Global Health Innovation Fund (MGHIF) and TechBio-focused ARTIS Ventures. Other backers included new investors included First Spark Ventures, The Venture Collective, Humain Ventures, LongeVC, and Not Boring Capital, and existing investors. Prem Tumkosit, Managing Director of Merck Global Health Innovation Fund, has joined UNP’s board of directors.
The company intends to use the funds to advance the development of its technology platform and expand its focus beyond oncology into new opportunities.
Led by CEO Cameron Pye, Unnatural Products is a biotech company whose platform combines parallel experimentation and machine learning to create entirely new drugs by engineering synthetic molecules to mimic nature’s macrocycles.
FinSMEs
19/12/2023